25C-NBOMe

25C-NBOMe

25C-NBOMe

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

25C-NBOMe

Also known as:

  • 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine[ACD/IUPAC Name]
  • 2-(4-Chlor-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamin[German][ACD/IUPAC Name]
  • 2-(4-Chloro-2,5-diméthoxyphényl)-N-(2-méthoxybenzyl)éthanamine[French][ACD/IUPAC Name]
  • 4-CHLORO-2,5-DIMETHOXY-N-(2-METHOXYBENZYL)PHENETHYLAMINE
  • 9FGW3C260N
  • Benzeneethanamine, 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-[ACD/Index Name]
  • N-(2-Methoxybenzyl)-2-(4-chloro-2,5-dimethoxyphenyl)ethanamine
  • [2-(4-Chloro-2,5-dimethoxy-phenyl)-ethyl]-(2-methoxy-benzyl)-amine
  • [2-(4-chloro-2,5-dimethoxyphenyl)ethyl][(2-methoxyphenyl)methyl]amine
  • 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine
  • 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
  • 25C-NBOMe
  • MFCD16659701[MDL number]
  • UNII:9FGW3C260N
  • UNII-9FGW3C260N

A relatively new and popular research chemical. A short acting psychedelic related to 2C-C with similar effects to LSD, though more visual with less of a ‘head-trip.’ Frequently mis-sold as LSD. Causes an uncomfortable body load and has caused several deaths even within regular dose ranges.

Summary

It is a member of the 25x-NBOMe series, a recently discovered group of potent psychedelic compounds derived from the 2C-x family. The name 25C-NBOMe, which is short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic 2C-C. It was discovered in 2003 by Ralf Heim at the Free University of Berlin, and subsequently investigated by a team at Purdue University led by David Nichols.

It has been studied in its radiolabelled form as a potential ligand for mapping the distribution of serotonin-2A receptors in the brain using positron emission tomography (PET). The first reports of human use appeared in 2010 following its appearance on the online research chemical market. Subjective effects include stimulation, open and closed-eye visuals, time distortion, euphoria, and ego loss.

25C-NBOMe’s effects are sometimes compared to those of LSD or DOx. However, it is reported to have stronger visual effects and less cognitive and emotional effects like ego loss and introspection. Additionally, 25C-NBOMe is reported to be considerably more stimulating than other psychedelics.

Serious side effects are more common and include nausea, muscle tension, anxiety, cardiovascular effects, and seizures. It is worth noting that members of the NBOMe series are not orally active and should be administered sublingually (by holding it into one’s mouth and allowing it to absorb over a period of 15 minutes). 25C-NBOMe can also be vaporized and inhaled for more rapid and powerful effects and a shorter duration.

However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are active in the microgram range as it significantly increases the risk of overdose. 25C-NBOMe is also sometimes sold as a counterfeit version of LSD due to its similar effects and ability to be laid onto blotter paper. Very little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe.

However, it has been associated with many deaths and hospitalizations which suggests that it has a significantly worse toxicity profile than classical psychedelics like LSD or psilocybin mushrooms. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. It is highly advised to use harm reduction practices if using this substance.

History

Chemistry

25C-NBOMe

25C-NBOMe

25C-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4.

It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right.

25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family.

This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Common Name2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
Systematic name2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
FormulaC_{18}H_{22}ClNO_{3}
SMILESCOc1ccccc1CNCCc2cc(c(cc2OC)Cl)OC
Std. InChiInChI=1S/C18H22ClNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
Std. InChiKeyFJFPOGCVVLUYAQ-UHFFFAOYSA-N
Avg. Mass335.8252 Da
Molecular Weight335.8252
Monoisotopic Mass335.128815 Da
Nominal Mass335
ChemSpider ID24583389

Subscribe for the latest updates

Dosing Guide

Sublingual
Threshold50-250ug
Light250-500ug
Common500-750ug
Strong750-1250ug+

Duration

25C-NBOMe Duration Data
Onset45-90 minutes
Duration4-10 hours
After-effects1-24 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
EffectsMild OEV's, strong CEV's, A sense of well being and contentedness.
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance25c has an extremely prevalent tolerence, with users reporting a strong cross tolerence with LSD, mushrooms, 2c-X, 25x, and DOx chemicals. Tolerence lasts roughly 2 weeks, depending on the user.
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

25C-NBOMe has efficacy at the 5-HT2A receptor where it acts as a potent partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. In comparison to 2C-C, the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD. In comparison to LSD however it is only a third of the potency.

Subjective Effects

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical Effects

Psychological Effects

The cognitive effects of 25C-NBOMe are commonly described as being notably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for user to report feeling that their thought stream has maintained a normality in style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

Visual Effects

Enhancements

Distortions

Geometry

25C-NBOMe visual geometry is often described as very similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics, they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages, which seem lower in proportion to the accompanying physical effects when compared to that of 25I-NBOMe.

The behavior of 25C-NBOMe geometry leads to Level 8A visual geometry with Level 8B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the user stares at a central point. This eventually envelopes the visual field and creates the sensation that the user has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.

Hallucinatory states

25C-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 - 5 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT. This can be considered as on par with and identical in behaviour to that of LSD and 25I-NBOMe.

These effects include:

Auditory Effects

Sensory Effects

  • Dosage independent intensity - While the reasons for this are not understood, many reports suggest that this substance can produce unexpectedly strong or weak effects even when taken at the seemingly same dose in an unpredictable manner. This may contribute to the relative risk it is poses compared to most other psychedelics.
  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

Transpersonal effects on 25C-NBOMe are thought to occur with less frequency than classical psychedelics such as LSD, psilocybin mushrooms, and mescaline.

Legal Status

  • Austria: Since June 26, 2019, 25C-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
  • Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
  • China: As of October 2015 25C-NBOMe is a controlled substance in China.
  • Germany: 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.
  • Italy: 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.
  • Latvia: 25C-NBOMe is a Schedule I controlled substance.
  • New Zealand: 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
  • Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
  • Sweden: 25C-NBOMe is classed as Schedule I.
  • United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
  • United States: Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.

  • References

    1. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    2. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
    3. Michael Robert Braden. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
    4. https://www.ncbi.nlm.nih.gov/pubmed/21174090
    5. http://bitnest.ca/external.php?id=%18%3A3%172%1BE%24K%5BG%21%24%7D%04%04V
    6. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24397362
    7. 25C-NBOMe--new potent hallucinogenic substance identified on the drug market (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22989597
    8. http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml
    9. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid - https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    10. Fatal intoxication with the new designer drug 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26324189
    11. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
    12. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
    13. https://erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    14. https://erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    15. https://erowid.org/chemicals/nbome/nbome_death.shtml
    16. https://onlinelibrary.wiley.com/doi/full/10.1002/dta.2751
    17. https://www.sciencedirect.com/science/article/abs/pii/S0033318218304882
    18. https://www.sciencedirect.com/science/article/abs/pii/S0378427418317533
    19. https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig
    20. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    21. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
    22. 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
    23. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
    24. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    25. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    26. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
    27. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
    28. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
    29. ‘Legal high’ DIME not so legal | http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/
    30. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
    31. Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html
    32. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
    33. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
    34. DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.